These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 20282730)

  • 1. Chemical, clinical and immunological studies on the products of human plasma fractionation; the coagulation defect in hemophilia; the effect in vitro and in vivo on the coagulation time in hemophilia of a prothrombin and fibrinogen-free normal plasma and its derived protein fractions.
    LEWIS JH; SOULIER JP; TAYLOR FH
    J Clin Invest; 1946 Nov; 25(6):876-9. PubMed ID: 20282730
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemical, clinical and immunological studies on the products of human plasma fractionation; the coagulation defect in hemophilia; an in vitro and in vivo comparison of normal and hemophilic whole blood, plasma and derived plasma protein fractions.
    LEWIS JH; DAVIDSON CS
    J Clin Invest; 1946 Nov; 25(6):870-5. PubMed ID: 20282729
    [No Abstract]   [Full Text] [Related]  

  • 3. CHEMICAL, CLINICAL AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXIII. THE COAGULATION DEFECT IN HEMOPHILIA: THE EFFECT IN VITRO AND IN VIVO ON THE COAGULATION TIME IN HEMOPHILIA OF A PROTHROMBIN AND FIBRINOGEN-FREE NORMAL PLASMA AND ITS DERIVED PROTEIN FRACTIONS.
    Lewis JH; Soulier JP; Taylor FH
    J Clin Invest; 1946 Nov; 25(6):876-9. PubMed ID: 16695385
    [No Abstract]   [Full Text] [Related]  

  • 4. The relation of certain fractions of the plasma globulins to the coagulation defect in hemophilia.
    LEWIS JH; TAGNON HJ
    Blood; 1946 Mar; 1():166-72. PubMed ID: 21015979
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hemophilia and other hemophilia-like diseases].
    Matsuoka S
    Nihon Rinsho; 1970 Mar; 28():Suppl:1014-5. PubMed ID: 5464417
    [No Abstract]   [Full Text] [Related]  

  • 6. Prothrombin utilization following addition of platelet confactor I concentrates to hemophilic plasma.
    JOHNSON JF; MAMMEN EF; SEEGERS WH
    Thromb Diath Haemorrh; 1959 Sep; 3():588-92. PubMed ID: 14407473
    [No Abstract]   [Full Text] [Related]  

  • 7. The coagulation defect in hemophilia with particular reference to the conversion of prothrombin to thrombin and the evolution of the prothrombin conversion accelerator.
    ALEXANDER B; DE VRIES A
    Blood; 1949 Jun; 4(6):752-8. PubMed ID: 18129761
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitor of human blood coagulation elicited by thrombin.
    Marciniak E
    J Lab Clin Med; 1972 Jun; 79(6):924-34. PubMed ID: 5025460
    [No Abstract]   [Full Text] [Related]  

  • 9. [Correction in vitro of A and B hemophilia by various dilutions of normal blood: modifications of clotting time and of prothrombin consumption].
    SOULIER JP; LARRIEU MJ
    Sem Hop; 1954 Aug 26-30; 30(52-53):3033-42. PubMed ID: 13195756
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of platelets on the in vitro response to prothrombin complex concentrates in F.VIII inhibitor plasma.
    Castaldi PA; Smith IL
    Pathology; 1980 Jan; 12(1):111-8. PubMed ID: 6769085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia: quantitative studies of the coagulation defect; a modified prothrombin-consumption test using erythrocytin.
    QUICK AJ; HUSSEY CV
    AMA Arch Intern Med; 1956 May; 97(5):524-31. PubMed ID: 13312694
    [No Abstract]   [Full Text] [Related]  

  • 12. ABNORMAL BLOOD COAGULATION IN CARRIERS OF HEMOPHILIA.
    MILLER SP; SIGGERUD J
    J Lab Clin Med; 1964 Apr; 63():621-37. PubMed ID: 14155450
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombotest mixing experiments in congenital coagulation disorders of the prothrombin complex and in coumarin treated patients. An additional evidence against the presence of an inhibitor in the latter.
    Girolami A; Patrassi O; Cella G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(3):463-70. PubMed ID: 72033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogenolytic demonstration of activation and inhibition of tryptase in plasma protein fraction-I (antihemophilic globulin).
    FERGUSON JH; TRAVIS BL; GERHEIM EB
    Proc Soc Exp Biol Med; 1947 Mar; 64(3):285-9. PubMed ID: 20293213
    [No Abstract]   [Full Text] [Related]  

  • 15. Normotest--thrombotest discrepancy in congenital coagulation disorders of the prothrombin complex and in coumarin-treated patients: a nonspecific phenomenon.
    Girolami A; Brunetti A; Patrassi GM
    Am J Clin Pathol; 1977 Jan; 67(1):57-60. PubMed ID: 831455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood platelets of hemophilia patients].
    Weibbbach G; Bührdel P; Domula M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1973; 100(1):131-43. PubMed ID: 4128511
    [No Abstract]   [Full Text] [Related]  

  • 17. MODIFICATIONS OF THE COAGULATION MECHANISM DURING PREGNANCY.
    PHILLIPS LL
    Mod Trends Hum Reprod Physiol; 1963; 15():190-204. PubMed ID: 14115154
    [No Abstract]   [Full Text] [Related]  

  • 18. Biophysical studies of blood plasma proteins; the effect of fibrinogen on prothrombin time.
    DEUTSCH HF; GERARDE HW
    J Biol Chem; 1946 Nov; 166(1):381-8. PubMed ID: 20273704
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies of hemophilia; the assay of the antihemophilic clot-promoting principle in normal human plasma with some observations on the relative potency of certain plasma fractions.
    ALEXANDER B; LANDWEHR G
    J Clin Invest; 1948 Jan; 27(1):98-105. PubMed ID: 18897631
    [No Abstract]   [Full Text] [Related]  

  • 20. [Capacity of activation of so-called deficient factors in hereditary blood coagulation disorders].
    Mingers AM
    Fortschr Med; 1976 Oct; 94(30):1723-5. PubMed ID: 1086815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.